Risk of candidiasis associated with interleukin-17 inhibitors:Implications and management

被引：0

作者：

Hazrat Bilal ^{[1
]}

Muhammad Nadeem Khan ^{[2
]}

Sabir Khan ^{[1
]}

Wenjie Fang ^{[3
]}

Wenqiang Chang ^{[4
]}

Bin Yin ^{[5
]}

NingJing Song ^{[6
]}

Zhongrong Liu ^{[7
]}

Dongxing Zhang ^{[8
,9
]}

Fen Yao ^{[10
]}

Xun Wang ^{[1
]}

Qian Wang ^{[1
]}

Lin Cai ^{[1
]}

Bing Hou ^{[11
]}

Jiayue Wang ^{[12
]}

Chunyan Mao ^{[12
]}

Lingxi Liu ^{[12
]}

Yuebin Zeng ^{[12
]}

机构：

[1] Department of Dermatology, Second Affiliated Hospital of Shantou University Medical College

[2] Faculty of Biological Sciences, Department of Microbiology, Quaid-I-Azam University

[3] Department of Dermatology, Changzheng Hospital, Second Military Medical University

[4] School of Pharmacy, Shandong University

[5] Department of Dermatovenereology, Chengdu Second People's Hospital

[6] Department of Dermatology, Tongren Hospital, Shanghai Jiao Tong University

[7] Department of Dermatology, First Affiliated Hospital of Guangzhou Medical University

[8] Department of Dermatology, Meizhou Dongshan Hospital

[9] Department of Dermatology, Meizhou People's Hospital

[10] Department of Pharmacy, Shantou University School Medical College

[11] Department of Clinical Laboratory, Skin and Venereal Diseases Prevention and Control Hospital of Shantou City

[12] Department of Dermatology, West China Second University Hospital, Sichuan University

来源：

真菌学(英文) | 2024年 / 15卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R519 [真菌与放线菌传染病];

学科分类号：

100401 ;

摘要：

The application of inte rleukin-17(IL-17) inhibito rs,including secukinumab,ixekizumab,brodalumab,and bimekizumab,are associated with elevated risk of candidiasis.These medications interfere with the IL-17 pathway,which is essential for maintaining mucosal barriers and coordinating the immune response against Candida species.The observational data and clinical trials demonstrate the increased incidence of candidiasis in individuals treated with IL-17 inhibitors.Brodalumab and bimekizumab pose a greater risk than secukinumab in eliciting candidiasis,whereas the data regarding ixekizumab are equivocal.Higher doses and prolonged treatment duration of IL-17 inhibitors increase the risk of candidiasis by compromising the immune response against Candida species.Prior to prescribing IL-17 inhibitors,healthcare professionals should comprehensively evaluate patients' medical histories and assess their risk factors.Patients should be educated on the signs and symptoms of candidiasis to facilitate early detection and intervention.Future research should focus on identifying the risk factors associated with candidiasis in patients receiving IL-17 inhibitors.Prospective studies and long-term surveillance are required to explore the impact of specific inhibitors on the incidence and severity of candidiasis and to evaluate the effectiveness of combination therapies,such as concurrent use of IL-17 inhibitors and prophylactic antifungal agents.

引用

页码：30 / 44+152 +152

页数：16

共 94 条

[31] Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study [J].